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Background: Acute mountain sickness (AMS) can occur in anyone going to a high altitude. Non-steroidal
anti-inflammatory drugs (NSAIDs) have been studied for the prevention of AMS with mixed results. In this
systematic review, we analyze all existing data on the use of NSAIDs to prevent AMS using the Lake Louise
Scoring System (LLSS) in different randomized clinical trials (RCTs).
Methods: Electronic literature searches for relevant studies were identified through MEDLINE, EMBASE,
SCOPUS, and Cochrane library up to June 2013. RCTs involving NSAIDs compared to placebo in patients
undergoingascenttoaheightofatleast3,800mwereincluded.Oddsratios(OR)werecalculatedandcombined
using fixed-effect model meta-analysis if I
20%. Differences between groupswere calculated using the inverse
variance of the standard mean differences. Between-study heterogeneity was assessed using the I
2 statistics.
Results: In three clinical trials involving 349 patients, AMS using LLSS occurred in 26.92% of patients on
NSAIDs and 43.71% on placebo (OR 0.43; CI [confidence interval] 0.270.69, I
20%, p0.0005), NNT6.
Minor outcome of end point Spo2 was not significant in the two groups (IV0.74; 95% CI 0.201.69,
I
281%, p0.12). Similarly, a change in Spo2 from baseline was also not significant in the two groups
(IV0.05; 95% CI 0.280.37, I
244%, p0.78).
Conclusion: NSAIDs might be a safe and effective alternative for the prevention of AMS. However, further
larger population studies and studies comparing NSAIDs to acetazolamide and dexamethasone in the future
may provide further data to its relative efficacy.
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E
very year, thousands of people travel to high-
altitude destinations worldwide for recreational
purposes, work-related activities, or pilgrimage.
Anyone traveling to a high altitude is at riskof developing
acute mountain sickness (AMS). However, it is seen
more commonly above 2,500m (8,250 feet) (1). The risk
also depends on the rate of ascent, prior acclimatization,
young age, history of prior altitude illness, and inborn
susceptibility (2, 3). As defined by the 1991 Lake Louise
Consensus (4), AMS is a group of symptoms associated
with hypobaric hypoxemia above 2,500m. It usually
manifests with headache, which is often associated with
fatigue, lightheadedness, anorexia, nausea and vomiting,
and disturbed sleep with frequent awakening (1, 3).
Typically, symptoms occur after 612 hours of ascent.
It is usually self-limited. However, if untreated it can
progress to the life-threatening high altitude cerebral
edema (HACE) (1, 5).
Although the mechanism of AMS/HACE is not well
understood, therapies commonly used for prophylaxis
such as acetazolamide and glucocorticoids in general
target the known physiological effects of AMS such as
fluid retention, hypoventilation, impaired gas exchange,
and heightened sympathetic response (2). Non-steroidal
anti-inflammatory drugs (NSAIDs) however have been
thought to work at the pathogenesis level, inhibiting the
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havesomeutilityinthepreventionofAMS.Thereareafew
studiesshowingeffectivenessofNSAIDsintheprevention
of AMS but they have been limited by their small sample
size. However, a systematic reviewof literaturewith regard
to NSAIDs and prevention of AMS is lacking. The aim of
this study is to synthesize and analyze the available
evidence, including the aforementioned clinical trials. As
the assessment of AMS is subjective and potentially prone
to bias, we chose to include only randomized, placebo-
controlled, double-blind studies that clearly defined the
diagnosis of AMS.
Methods
Studies assessing the use of NSAIDs versus placebo as an
intervention for the prophylaxis of AMS were considered
for inclusion in our study. Studies were required to
randomize the participants to either NSAIDs or placebo
group before ascent. A protocol for this meta-analysis
was prospectively devised that details the background,
objectives and eligibility criteria of studies, outcomes, and
statistical methods. This is available for review upon
request to investigators.
Literature search and data extraction
The PRISMA statement for reporting systematic re-
views recommended by the Cochrane Collaboration was
followed for conducting this meta-analysis (Fig. 1).
Systematized search of MEDLINE, EMBASE, SCOPUS,
Cochrane library, and clinical trials.gov (inception to
August 2013) were carried out to identify eligible random-
ized clinical trials (RCTs). PubMed, Cochrane Library,
EMBASE, and SCOPUS databases were searched using
the search terms under two search themes and com-
bined using the Boolean operator ‘AND’. For the theme
‘NSAID’, we used a combination of MeSH, entry terms,
and text words: NSAID, NSAIDs, non-steroidal anti-
inflammatory drugs, ibuprofen, carbasalate, naproxen,
aspirin, salicylate, salicylic acid, and ketorolac. For the
theme ‘Acute Mountain Sickness’, AMS, acute mountain
sickness, mountain sickness, high altitude cerebral edema,
HACE, and high altitude cerebral oedema were all used.
Nolanguagerestrictionswereused.Bibliographiesbelong-
ing to included papers, known reviews, and relevant
articleswere looked into for additional trials. To minimize
data duplication as a result of multiple reporting, we
compared papers from the same author. Two authors (SG
and MRA) screened and retrieved reports and excluded
irrelevant studies. Relevant data were extracted by two
authors (SG and MRA) and checked by another (PK and
RP). An additional investigator (AP) participated in the
review process when uncertainty about eligibility criteria
arose. From each study, we extracted and tabulated mean
age, gender, altitude, type, and dose of NSAIDs used as
well as primary and secondary indicators of efficacy and
adverse events (Table 1).
Study selection and evaluation for the review
We selected studies that were randomized and compared
the use of NSAIDs versus placebo in the prevention of
AMS. The steps of the literature search process are
summarized in Fig. 1.
The eligibility criteria for this meta-analysis were
1) randomized controlled trials (RCTs) of healthy human
subjects between age 18 and 65, 2) population residing in
analtitudelessthan1,240mwithascentofatleast3,800m
above the sea level, 3) prophylaxis with either NSAIDs or
placebo for AMS, and 4) AMS clearly defined using the
Lake Louise Scoring System (LLSS). The RCTs were
excluded if they were unrelated to the current research
topic and if they did not primarily assess prevention of
AMS (e.g. studies looking at aspirin for the prevention of
high altitude headache, or HAH). The studies were also
excludediftheparticipantswerepregnantorthoughttobe
pregnant, lived or slept at an altitude greater than 1,240 m
in the past week, were indigenous or local population (due
tophysiologicaladaptationtothealtitude),hadsymptoms
consistent with AMS at baseline, signs or symptoms of a
substantial acute infection, taken any NSAIDS, steroids
or acetazolamide within 13 days before enrolment or had
a history of HACE or pulmonary edema. Conference
abstracts were not included in our meta-analysis.
Three studies were included in our review and were
slightly different. The first study by Gertsch et al. was an
RCT looking at the preventive effect of 600mg of
ibuprofen or placebo three times daily before and during
the ascent on 232 Western trekkers from 4,240 or 4,358 m
to 4,928 m in Mt. Everest in Nepal. The second study by
Lipmanetal.recruited75healthyadultvolunteerslivingat
low altitude who were randomized to receive ibuprofen or
placebothreetimesdailystarting6hoursbeforetheascent
from 1,240 to 3,810 m in White mountains in California.
Similarly, a third study by Kayser et al. looked at the
preventive effect of calcium carbasalate 380 mg/day or
placebo on altitude-naive subjects from sea level to 5,896 m.
All of these RCTs looked at the incidence and severity of
AMS as measured by LLSS as their primary outcome.
Assessment of risk of bias
The quality of included studies were independently
evaluated by two reviewers (SG and MRA) using the
guidelines provided by Cochrane Collaboration tool for
assessing risk of bias (6). All of the studies were assessed
for random sequence generation, allocation concealment,
blinding of participants, incomplete outcome data, and
selective outcome reporting and free from other biases.
Each domain of risk was assigned as ‘adequate’ for low
risk, ‘inadequate’ for low risk, and unclear in cases not
mentioned (Supplementary Table 2).
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The primary outcome measure for this study was preven-
tionofAMSusingLLSS(scoreusedtodiagnoseAMSand
its severity developed by panel of experts in 1991). All the
included studies used Lake Louise Criteria for diagnosing
AMS. According to the Lake Louise consensus criteria,
AMS is defined as the presence of headache with at least
one other symptom after recent ascent to altitude: gastro-
intestinal (GI) disturbance (anorexia, nausea, vomiting),
dizziness/lightheadedness,insomnia,orfatigue.Thesefive
symptomsarescoredasperthedegreeoftheirseverityand
a composite score of 3 or more is consistent with a diag-
nosis of AMS (7). The studieswithout a clear definition of
AMSorproperrandomizationwereexcluded.Inthestudy
by Meehan et al., Environmental Symptom Questionnaire
(ESQ) was used to identify AMS. However, the data was
reported in terms of severity of AMS and the incidence of
AMS was unclear among the study population (8). Hence,
Meehan’s study had to be excluded from our meta-
analysis. Secondaryoutcomes included difference in arter-
ial oxygen saturation (SpO2) and the severity of headache
defined by the Visual Analog Scale (VAS).
Statistical analysis
All outcome comparisons and treatment effects were cal-
culatedwithRevManversion5.2(CochraneCollaboration,
Fig. 1. PRISMA ﬂow diagram showing the screening and inclusion of the studies.
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and 95% confidence intervals (CI) were estimated using a
fixed effects method if I
2 was 0. To control for heteroge-
neity if present, random effect models were used for this
meta-analysis as their assumption account for presence of
variability among the studies. We also performed a sensi-
tivity analysis using the inverse variance method to pool
ORs that were adjusted for baseline differences between
the two treatment arms. We calculated the I
2 statistics to
evaluate the percentage of heterogeneity among the trials.
When interpreting heterogeneity, I
2 values less than 30%
were considered as low heterogeneity, less than 60% as
moderate, and greater than 60% as high (9). A P-value of
B0.05 was used as the level of significance. The results are
reported in a forest plot with 95% CI. ORswere calculated
for each outcome. Cochrane calculator was used to
determine the number needed to treat (NNT) to prevent
one event of AMS.
Results
Included studies
Three studies satisfied inclusion criteria for this meta-
analysis. The studies were carried out in Mount Everest,
Nepal; Mount Kilimanjaro, Tanzania; White Mountains,
California, USA (2, 4, 9). Both males and females were
included in these studies with a total of 349 participants
(74% males). The height of the altitude ranged from 3,810
to 5,896 m with a mean of 4,801 m. Of the included
studies, two studies evaluated the effect of ibuprofen
with placebo (1, 10) and one study compared calcium
carbasalate with placebo (11). All of the studies used LLS
for the diagnosis of AMS (1, 10, 11). For a detailed
description of the study characteristics, please refer to
Table 1.
Prevention of AMS in all included trials
In three clinical trials involving 349 patients, AMS as
defined by LLSS occurred in 49 of 182 (26.92%) treated
with NSAIDs and in 73 of 167 (43.71%) treated with
placebo. The combined effect size was OR0.43 (95% CI
0.270.69, Z3.47, P0.0005, I
20%). The absolute
risk reduction was 16.8%. The NNT to prevent AMS was
six (Fig. 2).
Sensitivity analysis
A sensitivity analysis was performed including studies
that used only ibuprofen for a total of 318 participants.
Again, this was assessed using LLSS. The combined
effect size OR0.43 (95% CI 0.270.69, Z3.47, P
0.0005, I
20%). AMS occurred in 49 of 167 (29.34%)
treated with ibuprofen and 73 of 151 (48.34%) treated
with placebo. The absolute risk reduction was 19.00%.
The NNT to prevent AMS was five (Supplementary
Fig. 3).
Subgroup analyses
Subgroup analysis of headache severity using VAS was
alsofoundtobesignificantintwogroups(inversevariance
of standard mean difference (IV)0.29; 95% CI
0.51 0.07, I
20%, p0.01). Minor outcome of
end point Spo2 was not significant in the two groups
(IV0.74; 95% CI 0.201.69, I
281, p0.12).
Table 1. Baseline characteristics of the studies
Study setting
Final
altitude
(meter) Participants Intervention Outcomes Notes
Gertsch 2012,
Mt Everest
Nepal
4,928 N232 mean 37 years,
65% male, intervention
123 (mean age 38), control
109 (mean age 36)
600 mg of ibuprofen three
times daily, visually matched
placebo, treatment for 12
days depending on ascent
Diagnosis of
AMS as
defined by
LLSS
Participants were recruited
at Pheriche (4,280 m) or
Dingboche (4,358 m) which
may have introduced selection
bias or reduced the incidence
of AMS among participants
Kayser 2008, Mt
Kilimanjaro
5,896 N75, mean age 37
years, 91% male,
intervention 15, placebo
16
Carbasalate 380 mg/day,
visually matched placebo,
treatment for 6 days
Diagnosis of
AMS as
defined by
LLSS
Mixed study design; two
controlled arms comparing
placebo to calcium
carbasalate, third uncontrolled
arm for
subjects who opted out
for prophylactic acetazolamide
Lipman 2012,
White
mountains,
California
3,810 N86, mean age 36.6,
67% male, intervention 44
(mean age 38.4), placebo
42 (mean age 34.8)
Four doses of ibuprofen 600
mg, visually matched
placebo, treatment for 1 day
Diagnosis of
AMS as
defined by
LLSS
Participants recruited at 1,240
m, possible mild degree of
acclimatization
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0.37, I
244%, p0.78) (Supplementary files 2 and 3).
Discussion
The incidence and severity of AMS can be lowered by the
use of acetazolamide or dexamethasone (3, 12). However,
the use of NSAIDs continues to be an area of debate.
This is, to the best of our knowledge, the first systematic
review and meta-analysis of NSAIDs in the prevention of
AMS. It summarizes all the available evidence on the
efficacy of NSAIDs in the prevention of AMS. An
extensive database search identified 22 studies of interest,
out of which only three met our inclusion criteria. A
study by Ho B et al. using ibuprofen 400 mg three times
daily was not included in our study since this study
looked at a different outcome (hypoxic ventilatory
response rather than AMS) (13). Our analysis incorpo-
rated 349 patients from these three studies, which try to
overcome the limitation that the previous trials faced due
to low sample size. Analysis of data from these trials
suggests that NSAIDs might be an effective alternative
for the prevention of AMS, which is consistent with the
findings of two of the RCTs included in the study (1, 10).
It is well known that the baseline risk of AMS depends
on the rate and mode of ascent, altitude reached, level
of prior acclimatization, age and individual susceptibility
(11). The trials relating to acetazolamide in the prevention
of AMS show that it may be less effective in steep climbing
profile settings. Also the dose of acetazolamide remains a
subject of debate, and further studieswill be needed in this
regard (3). In our review, a separate analysis for rate and
mode of ascent could not be performed as not all of the
included studies clearly mentioned this.
In two of the included studies (Lipman and Gertsch),
ibuprofen 600 mg three times daily was used. The total
doses of ibuprofen used before the ascent varied among
the trials. While Lipman et al. used a single dose of
ibuprofen, Gertsch et al. used three different doses of
ibuprofen before the ascent. Similarly, in another study by
Kayser et al., participants were given calcium carbasalate
(380 mg/day equivalent to approximately 300 mg acet-
ylsalicylic acid). This study did not find carbasalate to be
effective for the prevention of AMS. However, these
results should be viewed with caution as the study lacked
sufficient power (n31). Our review suggests the possible
efficacy of NSAIDs for the prevention of AMS. However,
larger studies are needed to establish the validity of these
findings. Moreover, optimum dosage and timing of these
requires further study. One study has been done with a
head-to-head comparison between NSAIDs and acetazo-
lamide, which found similar efficacy of NSAIDs in the
prevention of AMS (10). The previous studies relating to
the prevention of AMS with acetazolamide and dexa-
methasone demonstrated that the NNT to prevent one
case of AMS with acetazolamide ranges from 3 to 8 (14)
and 2 to 4 with dexamethasone (15). In our review,
the NNT to prevent AMS was found to be six, which is
comparable with that of acetazolamide. Also in our
subgroup analysis, ibuprofen was found to have a NNT
of five. Hence, we suggest that ibuprofen might be a
reasonable alternative for the prevention of AMS. We
took into account the standard LLSS for AMS for
uniformity. Previous studies with aspirin in the past
demonstrated a significant protective effect of aspirin
for HAH (16, 17). However, these studies were not
included in our analysis since they only looked at head-
ache incidence and not AMS in its entirety. Our review
also shows that NSAIDs help in the prevention of
headache (using VAS) (1, 10). Since headache is an
important feature of AMS, there are concerns that the
masking of headache by NSAIDs could potentially make
the diagnosis difficult. Future studies are needed to
address this potential risk.
There was no significant difference in the endpoint
SpO2 or change from baseline between the participants.
This is in sharp contrast to the increased resting SpO2
notedwithacetazolamidewhichisattributedtoanincrease
in ventilation and improved oxygenation (11). Therefore,
this further supports the hypothesis that NSAIDs act
through a different pathway, likely at the cellular level by
modulating inflammation rather than increasing the
ventilation.
NSAIDs are generally well tolerated. Significant side
effects include GI upset and kidney injury, especially in
dehydrated patients. A possible serious complication
associated with NSAIDs is a risk of GI bleed, which
may be significantly increased at high altitudes where the
incidence of gastric erosions has been shown to increase.
However, all of the studies looking at this potential
Fig. 2. Meta-analysis of AMS incidence using the LLSS. Comparator: NSAIDs versus placebo.
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used acetazolamide is not without side-effects such as
paresthesia, dizziness, confusion, fatigue, taste distur-
bance, nausea, vomiting and polyuria. Similarly, dexa-
methasone is associated with significant side effects such
as adrenal suppression. It should be taken until descent if
started due to concerns for loss of protective effect and
rebound symptoms when withheld abruptly (2, 20).
Our findings need to be interpretedwith caution. Small
sample size, subjective scoring system and only one
study comparing NSAIDs to the proven therapies for
prevention of AMS are the most concerning limitations.
We also suggest that pharmacological agents should not
replacetheprovenpreventivemeasuressuchasslowascent
for acclimatization. Finally, one should bear in mind that
AMScanstill occurin rapidlyascendingnon-acclimatized
climbers with any of the prophylactic agents.
Limitations
Our study has several limitations. Although we included
only those studies that clearly defined the diagnosis of
AMS by using LLSS, the LLSS scoring system itself is
prone to subjective bias. Since headache is one of the five
components of LLSS, any drug that may decrease head-
ache can potentially lower the scores thus falsely giving
an impression of improved outcomes on VAS. A similar
possibility exists with dexamethasone, which may lower
LLSS due to its anti-emetic action. Since the endpoints
used to measure the efficacy of NSAID like headache
have this inherent flaw, better objective measures of
outcome would have been helpful.
Similarly, there were differences in the study design of
the included trials. Gertsch et al. studied the ascent from
around 4,000 to 5,000 m while Lipman et al. studied the
ascent from 1,240 to 3,810 m. The other study by Kayser
etal.wasdoneinclimbersstartingatsealevelandreaching
a final altitude of 3,810 m. Two of these studies (Gerstch
and Lipman et al.), that showed the benefits of ibuprofen,
constitutedapproximately91%ofthesubjects.Thesmaller
trial by Kayser et al. using carbasalate did not show any
benefit. With this systematic review, we attempt to
synthesize the role of NSAIDs in the prevention of AMS
with the currently available data. Due to the various issues
withthestudiesasoutlinedabove,itishardtoreachafinal
conclusion at this point. Hence, further well-designed
studies in non-acclimatized patients, with broader ranges
of altitude needs to be conducted. Some of the smaller
trials have shown a superior effect of a combination of
acetazolamide and dexamethasone compared to acetazo-
lamide alone (21, 22). However, there have been no trials
looking at the effect of NSAIDs and the other proven
therapies. Lastly, studies in the future would need to have
uniform criteria for the diagnosis of AMS and to quantify
its severity.
Conclusion
Our systematic review and meta-analysis suggests that
NSAIDs might be a safe and effective alternative for the
prevention of AMS. However, further larger population
studies will have to be done before recommending it as an
alternative to the commonly used acetazolamide or
dexamethasone. Also trials comparing NSAIDs to acet-
azolamide and dexamethasone in the future may provide
further data to its relative efficacy.
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